WCN26-7158 A case of Fabry disease with a favorable pregnancy course while continuing Migalastat treatment

Read full text Summarise with VIRAT
Authors: Yuya Sasatsuki, Maiko Nakayama, Tomoyuki Otsuka, Mikoto Fujishiro, Mai Akimoto, Masahiro Muto, Hisatsugu Takahara, Yusuke Suzuki, Hitoshi Suzuki
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene leading to deficient α-galactosidase A activity, glycosphingolipid accumulation, and life-threatening complications. Heterozygous women exhibit symptoms of Fabry disease in a variety of ways; some are asymptomatic or have mild symptoms, while others, like men, can develop complications in the heart, kidneys, and cerebrovascular system, affecting organs throughout the body. Treatment with migalastat is one of the standard of care, however, data regarding the safety of disease-specific therapies during pregnancy and post-partum remain limited.

Fields of Study & Subjects

Lysosomal Storage Disorders Research Metabolism and Genetic Disorders Glycogen Storage Diseases and Myoclonus

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105432–105432
Publication date
25 March 2026
Language
EN